![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Sanofi-Aventis |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00637715 |
Collection of the data on the safety and efficacy of the once daily administration of the alfuzosin preparation /Alfetim Uno® l0 mg/ at patients with lower urinary tract symptoms/complaints rendering possible the presence of benign prostatic hyperplasia, in the course of everyday practice
Condition | Intervention | Phase |
---|---|---|
Benign Prostatic Hyperplasia |
Drug: Alfuzosin |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Evaluation of the Effect of 10 mg Alfuzosin (Alfetim Uno®) o. d. in Patients Presenting Low-Urinary Tract Symptoms |
Enrollment: | 60 |
Study Start Date: | October 2003 |
Study Completion Date: | December 2004 |
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Responsible Party: | sanofi-aventis ( Study Director ) |
Study ID Numbers: | L_8758 |
Study First Received: | March 11, 2008 |
Last Updated: | April 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00637715 History of Changes |
Health Authority: | Hungary: OGYI (Országos Gyógyszerészeti Intézet) |
Neurotransmitter Agents Hyperplasia Alfuzosin Adrenergic Agents Prostatic Diseases Prostatic Hyperplasia |
Adrenergic Antagonists Cardiovascular Agents Adrenergic alpha-Antagonists Antihypertensive Agents Genital Diseases, Male |
Neurotransmitter Agents Prostatic Diseases Adrenergic Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Cardiovascular Agents Adrenergic alpha-Antagonists Antihypertensive Agents |
Genital Diseases, Male Pharmacologic Actions Hyperplasia Pathologic Processes Alfuzosin Prostatic Hyperplasia Therapeutic Uses Adrenergic Antagonists |